New Delhi:Pharma major Lupin on Friday said it has launched the generic version of Sugammadex injection indicated to reverse the effects of the muscle relaxants given during surgery in the United States. Following approval from the US Food and Drug Administration for its abbreviated new drug application, the company launched Sugammadex injection, 200 mg/2 mL and 500 mg/5 mL Single-Dose Vial in the US, Lupin said in a regulatory filing. Lupin's Sugammadex injection is the bioequivalent to Bridion injection of Merck, Sharp & Dohme LLC (Merck), the company said.

Avaada gets $1.3 bn

for 2,150 MW projects

New Delhi:Avaada Group on Friday announced the financial closure of $1.3 billion for its 2,150 MW renewable energy portfolio in Gujarat and Maharashtra. The financing has been sanctioned by Indian financial institutions, including State Bank of India (SBI), REC Ltd and Canara Bank, across four Special Purpose Vehicles (SPVs), Avaada Group said in a statement. The portfolio comprises 1.35 GW of hybrid renewable energy projects and 800 MW of utility-scale solar projects being developed for leading state distribution companies, Maharashtra State Electricity Distribution Company Limited and Gujarat Urja Vikas Nigam Limited.

Imarticus acquires

Singapore institute

New Delhi:Edtech firm Imarticus Learning has acquired Singapore-based BELLS Institute of Higher Learning providing it with access to learners in Southeast Asia, the company said on Friday. The deal size is estimated to be around Rs 800 crore, according to sources.

Wyndham Hotels

signs 11 properties

New Delhi:The world's largest hotel franchising firm Wyndham Hotels and Resorts signed 11 hotels across India during the first half of 2026 ended June, reflecting the long-term potential of the country's hospitality sector. During the first half of 2026, Wyndham continued its expansion into pilgrimage cities through the opening of Ramada Encore by Wyndham Ayodhya, and opened another destination in Nepal with Ramada by Wyndham Itahari Pashupati Marg, it added.

Emami eyes new brands for growth

New Delhi:Home-grown FMCG major Emami expects its strategic investments and new-age consumer brands portfolio to emerge as a key growth driver, increasing their contribution to consolidated turnover to around 25 per cent by FY30, the company said in its latest annual report.